AB-1005

Phase 2Small molecule

AAskBio Inc

AB-1005 is one of 2 small molecule programs targeting PARKINSON DISEASE (Disorder). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PARKINSON DISEASE (disorder)Not yet recruiting

PARKINSON DISEASE (disorder)Phase 2

Not yet recruiting

Competition

Competitive Landscape

4 competitors in PARKINSON DISEASE (disorder)

#DrugCompanyPhaseTrials

Best Oral Medication

UUniversity Hospital Tuebingen

Phase 3

1 2

AB-1005

AAskBio Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

PARKINSON DISEASE (disorder)

NCT07215403

Clinical

Trials by Indication[1]

PARKINSON DISEASE (Disorder)1 trial

Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

Not yet recruiting·AAskBio Inc·Phase 2·NCT07215403·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AB-1005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AB-1005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AB-1005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AskBio Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAskBio Inc

AB-1005

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

PARKINSON DISEASE (Disorder)1 trial

References

Drug Info

Quick Facts

Related News